doravirine (pifeltro) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drugs@FDA MeSH PubChem

Active Ingredient History

NOW
  • Now
Doravirine (MK-1439) is a nonnucleoside inhibitor of HIV reverse transcriptase (NNRTI). It displays excellent activities against not only WT viruses but also a broader panel of NNRTI-resistant viruses. Doravirine is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection in adults who have never taken HIV medicines before. Doravirine is always used in combination with other HIV medicines.   NCATS

Chemistry

  • SMILES: CN1C(=O)NN=C1CN2C=CC(=C(OC3=CC(Cl)=CC(=C3)C#N)C2=O)C(F)(F)F
  • InChIKey: ZIAOVIPSKUPPQW-UHFFFAOYSA-N
  • Mol. Mass: 425.749
  • ALogP: 2.65
  • ChEMBL Molecule:
    doravirine  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$33.1587 - $49.3158
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( doravirine (pifeltro), tenofovir (viread), lamivudine (epivir) - other name: doravirine/lamivudine/tenofovir disoproxil fumarate 100 mg-300 mg-300 mg oral tablet [delstrigo] )

Alternative names

doravirine | mk-1439

Organizations (38)

Research & Development (38)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (25)

Approved Indications (1)


 

HIV Infections (approved 2018)

Experimental Indications - Clinical Trial Phases 1-4 (25)


 

Art (Phase 3)

Body Weight Changes (Phase 3)

Central Nervous System (Phase 2)

Drug Interactions (Phase 4)

Drug-Related Side Effects and Adverse Reactions (Phase 1)

Drug Resistance (Phase 4)

Fasting (Phase 3)

Gender Dysphoria (Phase 1)

Heart Disease Risk Factors (Early Phase 1)

HIV (Phase 4)

HIV-1 (Phase 3)

HIV-Associated Lipodystrophy Syndrome (Phase 4)

HIV Infections (Phase 4)

Kidney Failure, Chronic (Phase 1)

Latent Tuberculosis (Phase 1)

Lipid Metabolism Disorders (Early Phase 1)

Metabolic Syndrome (Phase 3)

Minority Health (Phase 3)

Obesity (Phase 4)

Osteoporosis (Phase 4)

Pregnancy Complications (Phase 1)

Renal Insufficiency (Phase 4)

Transgender Persons (Phase 1)

Tuberculosis (Phase 4)

Weight Gain (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 52
  • # of Trial Organizations: 38

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue